Gilead Sciences (GILD.US) announced that it had struck a licensing agreement to produce the antiviral drug remdesivir in 127 countries, not including the US. The company’s will work with five generic drugmakers to produce the potential drug for coronavirus. Among them is Mylan (MYL.US), which is the world's largest producer of generic drugs.

Gilead Sciences (GILD.US) shares rose 1.96% in pre-market trading. If positive mood persists, then resistance at $86.16 per share may be tested. Source: xStation5
US Open: Hope for De-escalation Bolsters Wall Street Bulls
Apple earnings beat Wall Street estimates 🚨 iPhone sales below expectations
🗽S&P 500 companies with the record net margin since 2009 - FactSet data
Market Wrap: UK100 skyrockets after BoE 🇬🇧 🚀 Euphoric gain as ECB Lagarde speaks 🇪🇺 📈